Castresana J S, Rubio M P, Vázquez J J, Idoate M, Sober A J, Seizinger B R, Barnhill R L
Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Charlestown 02129.
Int J Cancer. 1993 Oct 21;55(4):562-5. doi: 10.1002/ijc.2910550407.
To investigate the role of the p53 tumor-suppressor gene in the development of human melanoma, loss of heterozygosity (LOH) of p53 was studied in 46 cases of melanoma by a polymerase-chain-reaction/restriction-fragment-length polymorphism (PCR/RFLP) analysis, and p53 mutations were assessed in 51 cases of melanoma by a polymerase-chain-reaction/single-strand-conformation polymorphism (PCR/SSCP) analysis. Frozen tumors and paraffin samples were used in the study. We were not able to detect any allelic loss in 12BstUI informative cases or any single mutation in exons 5 to 8 of the p53 gene. Our results, together with other findings at the DNA level, suggest that the p53 gene appears not to be commonly involved in the development of melanoma, at least by its most frequent mechanisms of deletion of one allele and/or mutation in the other.
